BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Medilink Midlands - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Medilink Midlands
X-ORIGINAL-URL:https://staging.medilinkmidlands.com
X-WR-CALDESC:Events for Medilink Midlands
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20210401T100000
DTEND;TZID=Europe/London:20210401T113000
DTSTAMP:20260410T094213
CREATED:20210218T140229Z
LAST-MODIFIED:20210218T140229Z
UID:18568-1617271200-1617276600@staging.medilinkmidlands.com
SUMMARY:WEBINAR: Cell Therapies: Bench to Bedside
DESCRIPTION:Cell therapies could be the magic bullet for treating many different and previously intractable diseases. However creating a new cell therapy is fraught with complexities – sourcing\, growing\, transporting cells and other components for these therapies can be difficult. This event in partnership with the Medical Technologies Innovation Facility (MTIF) brings together speakers from charity\, industry and academic sectors to provide considered insights into the different stages of cell therapy development from bench to bedside. \nThe webinar will address: \n• The sustainable and ethical sourcing of human adult derived biological products as starting materials and criteria to consider when selecting the correct starting materials.\n• Translating cell therapy into an implantable medical device with the adoption of substrates and scaffolds.\n• Understanding cellular interactions with substrates and hence need to evaluate in-vitro biocompatibility.\n• Reproducible and robust high throughput in-vitro testing for cell therapy performance validation. \nThere will be an opportunity to ask questions of our presenters in a Q&A session post presentation. \nThis webinar is open to all organisations seeking insight into cell therapy and the practicalities of development for patient use. \nThis free to attend event is held as part of the INSTILS programme – a project part-funded by the European Regional Development Fund\, click here to be re-directed to further information about the project. This event is classed as State Aid to participating businesses\, the value of which is £190\, but is delivered completely free of charge to participants. \nSpeaker Profiles  \n Mike Hannay\, Managing Director\, Medical Technologies Innovation Facility (MTIF) \n(CHAIR) \n  \n  \n  \n  \n Professor John Hunt\, Medical Technologies Innovation Facility (MTIF) \n  \n  \n  \n  \n \nKatie Griffee\, Business Development Manager\, Anthony Noaln Cell & Gene Therapy Services \nKatie supports cell and gene therapy researchers and developers access a scalable source of cellular starting material for R&D through to clinical application. Katie has a BSc in Biomedical Sciences and 7+ years’ experience working with pharmaceutical and biotech companies across Europe and the US. \n  \n  \n  \n \nEmma King\, Sales Engineer\, Hamamatsu Photonics UK Limited \nPresentation: High Throughput Screening (HTS) of stem cells using the Hamamatsu FDSSµcell \nEmma King studied Anatomy\, Developmental and Human Biology at Kings College London\, writing her thesis on cancer cell migration.\nAs part of the Research and Life Science group at Hamamatsu Photonics\, Emma is responsible for business development activities for Functional Drug Screening Systems (FDSS) in the UK. \n  \n  \n  \n \nAnn Kramer\, CEO\, The Electrospinning Company \nAnn Kramer is CEO of The Electrospinning Company\, an SME with a biomaterial platform with applications in regenerative medicine and cell therapy. Ann spent 20 years in agritech multinationals\, then 15 years in UK SMEs including Oxitec\, Immunocore and Biosyntha. \n  \n  \n  \n  \n  \n  \n  \n 
URL:https://staging.medilinkmidlands.com/event/webinar-cell-therapies-bench-to-bedside/
CATEGORIES:Project Event
ATTACH;FMTTYPE=image/jpeg:https://staging.medilinkmidlands.com/wp-content/uploads/2022/04/Emma-King.jpeg
ORGANIZER;CN="Jo Rudzki":MAILTO:info@medilinkem.com
END:VEVENT
END:VCALENDAR